Post-Vaccination pharmacovigilance Covid-19 in patients seeing a Daule health provider, Ecuador

Abstract

Introduction: Pharmacovigilance in post Covid-19 vaccination attempts to clarify myths of whether it is safe or not and maintains high expectations of control in the world before the pandemic. Objective: To identify adverse events after post Covid-19 vaccination and its morbidities, in a Health Center of Daule, Ecuador. Methodology: A cross-sectional, descriptive, cross-sectional research is performed, with an observational technique granted by health insurance provider Daule, Ecuador. Results: Of the study population 42.56% have the third dose, 38.97% used the Pfizer vaccine, 96.92% were healthy people without any medical condition who presented adverse event and 72.31% were notified by a health professional, the average age that manifested adverse events were from 31 to 60 years with 56.93%, the female sex had the highest percentage of adverse events, with 54.36%, the relevant adverse events in this study were pain at the vaccination site with 43.59%, headaches 32.31%, fever with 18.97%, the type of notification were mild with 72.31%, their waiting time in the occurrence of the adverse event was 30 minutes with 32.82% and they did not present greater combination with alcohol or psychotropics. Conclusions: The study is concluded indicating that the vaccine for Covid-19 is safe, since it does not present serious adverse events.